INSM

Rating neutralTentativeAI Memo

Insmed

As of 2026-10-02/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

high

Horizon

—

Key catalyst

ARIKAYCE FDA decision • 2027-01-28

Base target: $119 / p=50% prob

Biggest risk

BRINSUPRI uptake or reimbursement could disappoint against raised guidance; ARIKAYCE's review could be delayed or unsuccessful; and TPIP Phase 3 expansion increases spending before efficacy is established.

Invalidation

Break below $75 or thesis failure.

What would change my mind?

BRINSUPRI sustains its rapid launch trajectory, ARIKAYCE wins broader U.S. approval, and TPIP development advances, supporting a materially larger respiratory franchise. These outcomes remain conditional on commercialization, regulation and trials.

Research note

Recommendation

neutral

Confidence

high

As of

2026-10-02

Base target

$119

p=50%

Bull target

$155

p=25%

Bear target

$75

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

BRINSUPRI launch and guidance delivery
TPIP Phase 3 expansion
Additional TPIP Phase 3 initiation

BearKey bullets

ARIKAYCE Priority Review does not guarantee approval or a broader label; its existing U.S.
indication remains narrower.
Insmed release

WatchKey bullets

ARIKAYCE FDA decision

Summary

High-level snapshot

Recommendation

neutral

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $119 (p=50%)

Target spread vs base: +30% / -37%

Scenario probabilities

Bull Target: $155 (p=25%)Base Target: $119 (p=50%)Bear Target: $75 (p=25%)

Commentary

Company-source tone is constructive after Japanese BRINSUPRI approval and ARIKAYCE Priority Review, but the packet has no trusted recent-news set, verified price-reaction study, analyst revision history or sufficient social coverage. The zero-valued sentiment fields are unavailable-data placeholders, not measured readings. The $108.59 anchor is the October 1 close, not an October 2 intraday quote. Strong primary-source coverage and a dated catalyst calendar support monitoring, while the deterministic directional prior remains neutral. UTHR and LQDA are direct TPIP comparators, but neither covers Insmed's commercial portfolio.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

BRINSUPRI launch and guidance delivery
TPIP Phase 3 expansion
Additional TPIP Phase 3 initiation

Scenarios

Bull Target (Scenario probability)

$155 / p=25% prob

Base Target (Scenario probability)

$119 / p=50% prob

Bear Target (Scenario probability)

$75 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-28
ARIKAYCE FDA decision
The FDA granted Priority Review to Insmed's ARIKAYCE supplemental application and set a January 28, 2027 target action date. Approval could extend treatment to patients earlier in MAC lung disease; acceptance for review is not approval. [#PR-2026-09-21] Insmed release
Prob 70.00% • Move 12.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

BRINSUPRI launch and guidance delivery
2026-12-31
Second-quarter BRINSUPRI revenue was $309.2 million, up 49% sequentially, and Insmed raised 2026 revenue guidance to $1.25 billion–$1.40 billion. Japan approved BRINSUPRI in August. Sustained uptake, reimbursement and launch execution must support the guidance; approval alone does not establish sales. [#8-K-2026-08-06] [#SEC-8K-2026-08-06] SEC earnings exhibit Insmed Japan release
Prob 65% • Move 10% • Priced-in 70%
TPIP Phase 3 expansion
2026-12-31
At its second-quarter update, Insmed said the PALM-PAH and PALM-ILD Phase 3 studies were enrolling and anticipated starting a progressive pulmonary fibrosis Phase 3 study in the second half of 2026. Study initiation would broaden development but would not establish Phase 3 efficacy. [#SEC-8K-2026-08-06] SEC earnings exhibit
Prob 60% • Move 6% • Priced-in 45%
Additional TPIP Phase 3 initiation
2027-06-30
Insmed also anticipated initiating an idiopathic pulmonary fibrosis Phase 3 study in the first half of 2027. Timing and eventual clinical results remain uncertain. [#SEC-8K-2026-08-06] SEC earnings exhibit
Prob 55% • Move 5% • Priced-in 40%

Risks

ARIKAYCE Priority Review does not guarantee approval or a broader label; its existing U.S. indication remains narrower. Insmed release
BRINSUPRI launch results depend on patient uptake, reimbursement, adherence and adequate manufacturing supply despite Japanese approval. Insmed Japan release
TPIP's large projected peak-sales opportunity remains a company estimate, not proven Phase 3 efficacy or realized revenue. [#SEC-8K-2026-08-06] SEC earnings exhibit

Peers

Symbol	Summary
LQDA	Direct inhaled-treprostinil comparator for TPIP: Liquidia's YUTREPIA was approved for PAH and PH-ILD. Its PH-ILD position is uncertain after a September 30, 2026 patent ruling; Liquidia said it intends to seek removal of PH-ILD from the label, while the remedy and any appeal remain unresolved. This is a product-level comparison, not a whole-company valuation match. Liquidia approval release Liquidia litigation update
UTHR	Direct therapeutic comparator for TPIP's PAH and PH-ILD indications: United Therapeutics markets inhaled treprostinil as Tyvaso DPI. It is not a BRINSUPRI or ARIKAYCE comparator, so company-wide multiples remain imperfect. United Therapeutics release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

LQDA

Direct inhaled-treprostinil comparator for TPIP: Liquidia's YUTREPIA was approved for PAH and PH-ILD. Its PH-ILD position is uncertain after a September 30, 2026 patent ruling; Liquidia said it intends to seek removal of PH-ILD from the label, while the remedy and any appeal remain unresolved. This is a product-level comparison, not a whole-company valuation match. Liquidia approval release Liquidia litigation update

UTHR

Direct therapeutic comparator for TPIP's PAH and PH-ILD indications: United Therapeutics markets inhaled treprostinil as Tyvaso DPI. It is not a BRINSUPRI or ARIKAYCE comparator, so company-wide multiples remain imperfect. United Therapeutics release